CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
Folic aciddrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00120822
NCT00120822Phase 3Completed

A Study of the Effect of Folic Acid Supplementation on the Anti-malarial Action of Sulfadoxine-pyrimethamine When Used for Intermittent Preventive Treatment in Gambian Primigravidae.

London School of Hygiene and Tropical Medicine·interventional·Posted Jul 19, 2005·Updated Jan 12, 2017

In Brief

A Phase 3 clinical trial evaluating Folic acid for Malaria. Completed, across 1 site.

Detailed Summary

Supplementation with folic acid and iron is recommended for pregnant women in order to prevent them from developing anemia. In malaria endemic areas of Africa, the World Health Organization (WHO) now recommends that pregnant women should also be given sulfadoxine-pyrimethamine (SP) once a month after quickening to protect them against malaria which is especially harmful during pregnancy. However, folic acid is an antagonist of SP so there is a possibility that giving folic acid with SP could interfere with the ability of the latter to provide protection against malaria. To investigate this possibility Gambian primigravidae with malaria parasitemia have been given SP and folic acid at the same time or on separate occasions two weeks apart and the ability of SP to cure the malaria infection investigated.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalaria
CountriesThe Gambia

Timeline

Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 19, 2005
Enrollment StartJul 1, 2002
Study CompletionJan 1, 2004
TodayJul 2, 2026
Posted 21.0 years ago

Interventions

Folic aciddrug